Corvus Pharmaceuticals (CRVS) Times Interest Earned (2015 - 2026)
Corvus Pharmaceuticals (CRVS) posted quarterly Times Interest Earned of -$16.1 for Q1 2026, up 8.15% year-over-year from -$14.89 in Q1 2025, and up 13.8% quarter-over-quarter from -$18.68 in Q3 2025.
Corvus Pharmaceuticals (CRVS) Times Interest Earned (2015 - 2026) Analysis & Trends
Corvus Pharmaceuticals' Times Interest Earned history runs 12 years deep, the most recent figure standing at -$16.1 for Q1 2026.
- In Q1 2026, Times Interest Earned rose 8.15% year-over-year to -$16.1; the TTM figure through Mar 2026 stood at -$49.38 (up 4.81% YoY), while the FY2023 annual figure was -$0.28, up 98.53% from the prior year.
- Times Interest Earned for Q1 2026 stood at -$16.1, up from -$18.68 in the prior quarter.
- The five-year high for Times Interest Earned was -$5.82 in Q1 2024, with the low at -$59.65 in Q2 2025.
- The 5-year median for Times Interest Earned is -$16.1 (2026), against an average of -$18.17.
- The sharpest annual moves came in 2024 and 2025: Times Interest Earned soared 59.39% in 2024, then plunged 620.64% in 2025.
- Corvus Pharmaceuticals' Times Interest Earned stood at -$13.18 in 2022, then increased by 6.97% to -$12.26 in 2023, then sank by 65.32% to -$20.27 in 2024, then increased by 7.83% to -$18.68 in 2025, then climbed by 13.8% to -$16.1 in 2026.
- Business Quant data shows CRVS's Times Interest Earned at -$16.1 in Q1 2026, -$18.68 in Q3 2025, and -$59.65 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Corvus Pharmaceuticals | 1.25 Bn | 1.04 Bn | - | -24.24 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -24.24 |
| Mar 31, 2026 | -16.10 |
| Sep 30, 2025 | -18.68 |
| Jun 30, 2025 | -59.65 |
| Mar 31, 2025 | -17.53 |
| Sep 30, 2024 | -20.27 |
| Jun 30, 2024 | -8.28 |
| Mar 31, 2024 | -5.82 |
| Dec 31, 2023 | -12.26 |
| Sep 30, 2023 | -12.11 |
| Jun 30, 2023 | -12.22 |
| Mar 31, 2023 | -14.32 |
| Dec 31, 2022 | -13.18 |
| Sep 30, 2022 | -28.81 |
| Jun 30, 2022 | -16.20 |
| Mar 31, 2022 | -17.12 |
| Dec 31, 2021 | -16.81 |
| Sep 30, 2021 | -21.91 |
| Jun 30, 2021 | -27.34 |
| Mar 31, 2021 | -27.80 |